Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
BackgroundBrain metastases (BMs) indicate poor outcomes and are commonly excluded in immunotherapy clinical trials in advanced lung cancer; moreover, the effect of BM status on immunotherapy efficacy is inconsistent and inconclusive. Therefore, we conducted a meta-analysis to assess the influence of...
Main Authors: | Hao Hu, Zhi-Yong Xu, Qian Zhu, Xi Liu, Si-Cong Jiang, Ji-Hua Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.669398/full |
Similar Items
-
Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC
by: Qing LAN, et al.
Published: (2019-08-01) -
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
by: Lorenza Landi, et al.
Published: (2019-11-01) -
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
by: Qi Xiong, et al.
Published: (2021-07-01) -
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
by: Wei Xiong, et al.
Published: (2021-08-01) -
Systemic Immunotherapy for the Treatment of Brain Metastases
by: Justine V. Cohen, et al.
Published: (2016-03-01)